GV
VC Fund
Ludwigsburg, Germany
GV is a communication studio that develops successful printing concepts for direct marketing, letter shops, print, and address management. From conception, address and data administration, production, and lettershop through the postal service, their variety of services takes an all-encompassing view of the product.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries GV invests in
Stages GV invests in
Countries GV invests in
Investment Focus
Industry
- Health Care 3 (43%)
- Biotechnology 3 (43%)
- Therapeutics 2 (29%)
- B2B 1 (14%)
- iOS 1 (14%)
Stage
- Series B 3 (43%)
- Series A 2 (29%)
- Series C 1 (14%)
- Series E 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Oblenio Bio
|
Oblenio Bio is a biotechnology company that develops T-cell engager therapeutic candidates for autoimmune disease treatment. | $62M / Series B / Jun 25, 2026 | |
Sift
|
A connected company is a powerful company. At Sift, we created the easiest way to unleash the power of your people to propel your organization forward. We make finding the right expert at the right time, or connecting to anyone in your organization on the go simple—allowing you to drive organizational performance while saving you time. Sift helpsyou take your organization into the people-first, digital age with a solution that is as simple as it is powerful. | $42M / Series B / Mar 25, 2026 | |
SambaNova
|
SambaNova develops artificial intelligence computing infrastructure that combines AI processors, hardware systems, and software for deploying and managing AI inference workloads. Its platform supports cloud, on-premises, and hybrid deployments, enabling organizations to run and manage large language models and AI applications using compatible APIsand orchestration tools. | $350M / Series E / Feb 09, 2026 | |
Trace Neuroscience
|
Trace Neuroscience is a biopharmaceutical company that aims to extend the promise of genetic medicine to patients with neurodegenerative illnesses. | $101M / Series A / Nov 12, 2024 | |
Arda Therapeutics
|
Arda Therapeutics is a biotechnology company taking aim at chronic diseases and aging by eliminating the pathogenic cells that drive these conditions. Their approach starts by using single-cell data to identify pathogenic cells and specific markers to target them. They then design therapies to eliminate these - and only these - cells.Arda wasfounded in 2021 in the San Francisco Bay Area, CA. | $43M / Series A / Oct 01, 2024 | |
Gametime
|
Gametime sells last-minute tickets to the most popular events in sports, music, and theater. It makes finding the perfect live experience remarkably fast and easy. They curate an epic list of the most amazing possibilities in the city has to offer. Once the client selects their event it will examine over 10,000 potential seats and present them withthe 50 best values to select.Each curated seat option includes a panoramic high-resolution photo so their client can experience the actual view from their section. Navigate to the seat map to see price versus the location comparisons with true-to-life, full-color venue maps. Gametime delivers the tickets directly to the client's phone. Now they are offering sports, concerts, and theater events across the United States and Canada. | $30M / Series C / May 26, 2022 | |
The Pill Club
|
The Pill Club is a healthcare and wellness firm that focuses on birth control, skincare, and menstrual care, and offers women's well-being. | $41.9M / Series B / Jun 14, 2021 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does GV invest in?
GV invests primarily in Health Care, Biotechnology and Therapeutics startups, most often at Series B and Series A stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did GV last invest?
The most recent investment recorded for GV closed in Jun 2026. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
